Preferences of Patients with Chronic Hepatitis B – A Discrete Choice Experiment on the Acceptability of Functional Cure

References

• MacLachlan JH, Cowie BC. Hepatitis B virus epidemiology. Cold Spring Harb Perspect Med. 2015;5(5):a021410. doi:10.1101/cshperspect.a021410
   PubMed Web of Science ®Google Scholar
• Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97–107. doi:10.1046/j.1365-2893.2003.00487.x
   PubMed Web of Science ®Google Scholar
• Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212–2219. doi:10.1016/j.vaccine.2011.12.116
   PubMed Web of Science ®Google Scholar
• Hofstraat SHI, Falla AM, Duffell EF, et al. Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: a systematic review. Epidemiol Infect. 2017;145(14):2873–2885. doi:10.1017/S0950268817001947
   Web of Science ®Google Scholar
• Poethko-müller C, Zimmermann R, Hamouda O, et al. Die Seroepidemiologie der Hepatitis A, B und C in Deutschland: ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56(5–6):707–715. doi:10.1007/s00103-013-1673-x
   PubMed Web of Science ®Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–2128. doi:10.1016/S0140-6736(12)61728-0
   PubMed Web of Science ®Google Scholar
• Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: from discovery to regulatory approval. Hepatology. 2017;66(4):1296–1313. doi:10.1002/hep.29323
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Hepatitis B (chronic): diagnosis and management. Available from: https://www.nice.org.uk/guidance/cg165/resources/hepatitis-b-chronic-diagnosis-and-management-pdf-35109693447109. Accessed February 28, 2020.
   Google Scholar
• Kim WR. Emerging therapies toward a functional cure for hepatitis B virus infection. Gastroenterol Hepatol (N Y). 2018;14(7):439–442.
   Google Scholar
• Pham EA, Perumpail RB, Fram BJ, Glenn JS, Ahmed A, Gish RG. Future therapy for hepatitis B virus: role of immunomodulators. Curr Hepatol Rep. 2016;15(4):237–244. doi:10.1007/s11901-016-0315-9
   PubMedGoogle Scholar
• Yuen M-F, Wong DK-H, Fung J, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008;135(4):1192–1199. doi:10.1053/j.gastro.2008.07.008
   PubMed Web of Science ®Google Scholar
• Dusheiko G, Wang B, Carey I. HBsAg loss in chronic hepatitis B: pointers to the benefits of curative therapy. Hepatol Int. 2016;10(5):727–729. doi:10.1007/s12072-016-9738-1
   Web of Science ®Google Scholar
• Yip TC-F, Wong GL-H, Chan HL-Y, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol. 2019;70(3):361–370. doi:10.1016/j.jhep.2018.10.014
   PubMed Web of Science ®Google Scholar
• Kim G-A, Lim Y-S, An J, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 2014;63(8):1325–1332. doi:10.1136/gutjnl-2013-305517
   PubMed Web of Science ®Google Scholar
• Terrault NA, Bzowej NH, Chang K-M, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–283. doi:10.1002/hep.28156
   PubMed Web of Science ®Google Scholar
• EASL clinical practice guidelines. Management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–185. doi:10.1016/j.jhep.2012.02.010
   Web of Science ®Google Scholar
• Block TM. Explaining the hepatitis B drug pipeline. Available from: https://www.hepb.org/news-and-events/free-newsletters/fall-2016-b-informed-newsletter/explaining-the-hepatitis-b-drug-pipeline/. Accessed July 9, 2019.
   Google Scholar
• Krause A, Haberkorn U, Mier W. Strategies for the treatment of HBV/HDV. Eur J Pharmacol. 2018;833:379–391. doi:10.1016/j.ejphar.2018.06.030
   PubMed Web of Science ®Google Scholar
• Zeisel MB, Lucifora J, Mason WS, et al. Towards an HBV cure: state-of-the-art and unresolved questions–report of the ANRS workshop on HBV cure. Gut. 2015;64(8):1314–1326. doi:10.1136/gutjnl-2014-308943
   PubMed Web of Science ®Google Scholar
• Bekker-grob EWD, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ. 2012;21(2):145–172. doi:10.1002/hec.1697
   PubMed Web of Science ®Google Scholar
• Reed Johnson F, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013;16(1):3–13. doi:10.1016/j.jval.2012.08.2223
   PubMed Web of Science ®Google Scholar
• Hauber AB, González JM, Groothuis-Oudshoorn CGM, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19(4):300–315. doi:10.1016/j.jval.2016.04.004
   PubMed Web of Science ®Google Scholar
• Hoffman SD, Duncan GJ. Multinomial and conditional logit discrete-choice models in demography. Demography. 1988;25(3):415. doi:10.2307/2061541
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Hepatitis B - annual epidemiological report for 2017. Available from: https://ecdc.europa.eu/en/publications-data/hepatitis-b-annual-epidemiological-report-2017. Accessed July 7, 2019.
   Google Scholar
• Lim SG, Aung MO, Chung SWM, Soon CSL, Mak BHN, Lee KH. Patient preferences for hepatitis B therapy. Antivir Ther. 2013;18(5):663–670. doi:10.3851/IMP2482
   PubMed Web of Science ®Google Scholar
• Mühlbacher AC, Bridges JFP, Bethge S, et al. Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment. Eur J Health Econ. 2017;18(2):155–165. doi:10.1007/s10198-016-0763-8
   PubMed Web of Science ®Google Scholar
• Mühlbacher A, Bethge S. First and foremost battle the virus: eliciting patient preferences in antiviral therapy for hepatitis C using a discrete choice experiment. Value Health. 2016;19(6):776–787. doi:10.1016/j.jval.2016.04.007
   Web of Science ®Google Scholar
• Pacou M, Basso F, Gore C, et al. Patient and physician preferences for the treatment of chronic hepatitis C virus infections: does the perspective matter? Eur J Gastroenterol Hepatol. 2015;27(9):1063–1068. doi:10.1097/MEG.0000000000000410
   PubMed Web of Science ®Google Scholar
• Dintsios C-MR. Patient and physician preferences for the treatment of chronic hepatitis C virus infections: does the perspective matter? Eur J Gastroenterol Hepatol. 2016;28(3):362. doi:10.1097/MEG.0000000000000554
   Web of Science ®Google Scholar
• Lampertico P, Agarwal K, Berg T. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi:10.1016/j.jhep.2017.03.021
   PubMed Web of Science ®Google Scholar
• Allard N, Dev A, Dwyer J, Srivatsa G, Thompson A, Cowie B. Factors associated with poor adherence to antiviral treatment for hepatitis B. J Viral Hepat. 2017;24(1):53–58. doi:10.1111/jvh.12582
   PubMed Web of Science ®Google Scholar
• Liang LY, Wong GL-H. Unmet need in chronic hepatitis B management. Clin Mol Hepatol. 2019;25(2):172–180. doi:10.3350/cmh.2018.0106
   PubMed Web of Science ®Google Scholar
• Mueller S, Agostini H, Ehlken C, Bauer-steinhusen U, Hasanbasic Z, Wilke T. Patient preferences in the treatment of neovascular age-related macular degeneration: a discrete choice experiment. Ophthalmology. 2016;123(4):876–883. doi:10.1016/j.ophtha.2015.12.001
   PubMed Web of Science ®Google Scholar
• Petersen J, Thompson AJ, Levrero M. Aiming for cure in HBV and HDV infection. J Hepatol. 2016;65(4):835–848. doi:10.1016/j.jhep.2016.05.043
   Web of Science ®Google Scholar
• Gill US, Pallett LJ, Kennedy PTF, Maini MK. Liver sampling: a vital window into HBV pathogenesis on the path to functional cure. Gut. 2018;67(4):767–775. doi:10.1136/gutjnl-2017-314873
   Web of Science ®Google Scholar